In the MAD cohorts, the 140 mg dose Q4W resulted in a mean percent BW change of −2.0% at day 7 and −7.4% after three doses at day 78. The highest MAD dose of 420 mg Q4W resulted in a BW change of −4.9% at day 7 and −14.5% by day 85. In comparison, the...
Comparisons were made between fasting value at start of treatment to fasting value on Day 12 of treatment and comparison of maximum (peak) value on Day 12 vs. at treatment allocation with fasting value before treatment as covariate. Values of the area under the curve (AUC) of serum GLP-1 ...
To avoid ascertainment bias due to differences in duration of medication use in the two comparison groups, we created a new propensity score-matched cohort including the duration of follow-up based on per-protocol analysis, using the same previous specifications of the primary analysis. We used ...
Working with clinicians to improve patient outcomes through audit and personal feedback processes may help clinicians to recognise biases or gaps in their knowledge of guidelines [77,119]. Feedback may involve chart audits, patient surveys or direct observation, and has been suggested to increase ph...
Comparisons were made between fasting value at start of treatment to fasting value on Day 12 of treatment and comparison of maximum (peak) value on Day 12 vs. at treatment allocation with fasting value before treatment as covariate. Values of the area under the curve (AUC) of serum GLP-1 ...
The glucagon-like peptide-1 receptor agonist (GLP-1RA) dulaglutide has been shown to improve body weight and glycemic control and reduce major cardiovascular (CV) events. In Japan, dulaglutide is used at a fixed dose of 0.75 mg, which is lower than that in Europe and North America. However...
Comparison of the long-term effects of liraglutide and glimepiride monotherapy on bone mineral density in patients with type 2 diabetes. Endocr. Pract. Off. J. Am. Coll. Endocrinol. Am. Assoc. Clin. Endocrinol. 2016, 22, 406–411. [Google Scholar] [CrossRef] Iepsen, E.W.; Lundgren, ...